01

Precision Oncology Small Molecule Therapies

Cancer is a leading cause of death in China and worldwide. At Abbisko, we have assembled a R&D team with ample experience in characterizing various types of cancers and identify key genetic drivers of these diseases. Based on these findings, we are driven to discover and develop next generation innovative small molecule therapies to treat patients and improve the quality of their lives.  

02

Immuno-Oncology Small Molecule Therapies

Immuno-oncology (IO) therapies have revolutionized anti-cancer therapies in the past a few years. Drugs reactivating tumor-specific immune response harness the innate power of human immune system to eradicate cancer cells while sparing toxicity on normal cells caused by traditional targeted or chemotherapies. Several therapeutic antibodies against immune checkpoint receptors and ligands, such as PD1, CTL4 and PD-L1, have demonstrated striking and durable clinical responses across many types for tumors and became billion-dollar blockbusters. At Abbisko, we are developing a pipeline of next-generation small molecule immune modulators to improve efficacy, overcoming resistance, lowering side effects, and synergizing with first generation IO agents.